Kuhnil Pharm announced on the 16th that it has signed a sales partnership agreement for Epadel, an original version of the highly purified eicosapentaenoic acid (EPA) ethyl ester formulation, with Mochida Pharmaceutical in Japan.

Founded in 1913, Mochida Pharmaceuticals is a leading Japanese innovative pharmaceutical company that has played a leading role in the development of high-purity omega-3 fatty acid products.

Epadel (generic name: icosapent) is a highly purified EPA ethyl ester formulation developed by Mochida as the world's first medical drug. The drug is indicated for hyperlipidemia and ulcer, pain, and chilliness associated with arteriosclerosis obliterans in Japan.

Whang, byung-woo(tuai@dailypharm.com)